SCHEMBL6685191

SCHEMBL6685191

COc1ccc2c(c1)S(=O)(=O)N=C(c1c(O)c3cc(F)ccc3n(CCC(C)(C)C)c1=O)N2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.64
NR1I2 O75469 1/20 0.60
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PIK3R1 P27986 1/20 0.35
PIK3CA P42336 1/20 0.35
PLK1 P53350 3/20 0.34
CNR2 P34972 2/20 0.34
PER2 O15055 1/20 0.33
CRY1 Q16526 1/20 0.33
CRY2 Q49AN0 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
KDM4E B2RXH2 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
PGR P06401 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6686477 0.90 CYP2C9 (0.63) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6738466 0.89 CYP2C9 (0.63) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6692294 0.89 CYP2C9 (0.80) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6236224 0.89 CYP2C9 (0.80) CYP2C9NR1I2MAPK1HSD17B10PIK3R1
SCHEMBL6736631 0.84 CYP2C9 (0.65) CYP2C9NR1I2MAPK1HSD17B10PIK3R1
SCHEMBL6736597 0.81 CYP2C9 (0.76) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6233826 0.80 CYP2C9 (0.56) CYP2C9NR1I2MAPK1HSD17B10CNR2
SCHEMBL6255910 0.80 CYP2C9 (0.80) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6738292 0.80 CYP2C9 (0.65) CYP2C9NR1I2MAPK1HSD17B10CNR2
SCHEMBL6686456 0.80 HSD17B10 (0.61) CYP2C9NR1I2MAPK1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
WO-2004052312-A2 ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 CYP2C9 1218/4885NR1I2 1798/4885MAPK1 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.